Targeted and intracellular triggered delivery of therapeutics to cancer cells and the tumor microenvironment: impact on the treatment of breast cancer
- PMID: 21805188
- DOI: 10.1007/s10549-011-1688-7
Targeted and intracellular triggered delivery of therapeutics to cancer cells and the tumor microenvironment: impact on the treatment of breast cancer
Abstract
Limiting tumor invasion to the surrounding healthy tissues has proven to be clinically relevant for anticancer treatment options. We have demonstrated that, within a solid tumor, it is possible to achieve such a goal with the same nanoparticle by intracellular and triggered targeted drug delivery to more than one cell population. We have identified the nucleolin receptor in endothelial and cancer cells in tissue samples from breast cancer patients, which enabled the design of a F3-peptide-targeted sterically stabilized pH-sensitive liposome. The clinical potential of such strategy was demonstrated by the successful specific cellular association by breast cancer cells harvested from tumors of patients submitted to mastectomy. In vitro, the nanoparticle targeted the nucleolin receptor on a cell and ligand-specific manner and improved cytotoxicity of doxorubicin (used as a model drug) towards breast cancer and endothelial cells by 177- and 162-fold, respectively, relative to the commercially available non-targeted non-pH-sensitive liposomes. Moreover, active accumulation of F3-targeted pH-sensitive liposomes into human orthotopic tumors, implanted in the mammary fat pad of nude mice, was registered for a time point as short as 4 h, reaching 48% of the injected dose/g of tissue. Twenty-four hours post-injection the accumulation of the dual-targeted pH-sensitive nanoparticle in the tumor tissue was 33-fold higher than the non-targeted non-pH-sensitive counterpart. In mice treated with the developed targeted nanoparticle significant decrease of the tumor viable rim area and microvascular density, as well as limited invasion to surrounding healthy tissues were observed (as opposed to other tested controls), which may increase the probability of tumors falling in the category of "negative margins" with reduced risk of relapse.
Similar articles
-
Estrogen-anchored pH-sensitive liposomes as nanomodule designed for site-specific delivery of doxorubicin in breast cancer therapy.Mol Pharm. 2012 Jan 1;9(1):176-86. doi: 10.1021/mp200439z. Epub 2011 Nov 28. Mol Pharm. 2012. PMID: 22091702
-
Nucleolin overexpression in breast cancer cell sub-populations with different stem-like phenotype enables targeted intracellular delivery of synergistic drug combination.Biomaterials. 2015 Nov;69:76-88. doi: 10.1016/j.biomaterials.2015.08.007. Epub 2015 Aug 6. Biomaterials. 2015. PMID: 26283155
-
Toward a siRNA-containing nanoparticle targeted to breast cancer cells and the tumor microenvironment.Int J Pharm. 2012 Sep 15;434(1-2):9-19. doi: 10.1016/j.ijpharm.2012.05.018. Epub 2012 May 19. Int J Pharm. 2012. PMID: 22617794
-
Targeted drug delivery for breast cancer treatment.Recent Pat Anticancer Drug Discov. 2013 May;8(2):143-53. Recent Pat Anticancer Drug Discov. 2013. PMID: 23394116 Review.
-
Emerging nanotherapeutic strategies in breast cancer.Breast. 2014 Feb;23(1):10-8. doi: 10.1016/j.breast.2013.10.006. Epub 2013 Nov 8. Breast. 2014. PMID: 24215984 Review.
Cited by
-
Nucleolin‑based targeting strategies in cancer treatment: Focus on cancer immunotherapy (Review).Int J Mol Med. 2023 Sep;52(3):81. doi: 10.3892/ijmm.2023.5284. Epub 2023 Jul 21. Int J Mol Med. 2023. PMID: 37477132 Free PMC article. Review.
-
Evaluation of the Antitumour and Antiproliferative Effect of Xanthohumol-Loaded PLGA Nanoparticles on Melanoma.Materials (Basel). 2021 Oct 26;14(21):6421. doi: 10.3390/ma14216421. Materials (Basel). 2021. PMID: 34771946 Free PMC article.
-
Use of Targeted Liposome-based Chemotherapeutics to Treat Breast Cancer.Breast Cancer (Auckl). 2015 Aug 10;9(Suppl 2):1-5. doi: 10.4137/BCBCR.S29421. eCollection 2015. Breast Cancer (Auckl). 2015. PMID: 26309409 Free PMC article. Review.
-
Functionalized liposomes for targeted breast cancer drug delivery.Bioact Mater. 2023 Jan 2;24:401-437. doi: 10.1016/j.bioactmat.2022.12.027. eCollection 2023 Jun. Bioact Mater. 2023. PMID: 36632508 Free PMC article. Review.
-
Cell surface Nucleolin represents a novel cellular target for neuroblastoma therapy.J Exp Clin Cancer Res. 2021 Jun 2;40(1):180. doi: 10.1186/s13046-021-01993-9. J Exp Clin Cancer Res. 2021. PMID: 34078433 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous